These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22024846)

  • 21. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia.
    Bielamowicz S; Squire S; Bidus K; Ludlow CL
    Ann Otol Rhinol Laryngol; 2001 May; 110(5 Pt 1):406-12. PubMed ID: 11372922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
    Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
    Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
    Lee SJ; Kang MS; Choi HS; Lim JY
    Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined modality treatment of adductor spasmodic dysphonia.
    Silverman EP; Garvan C; Shrivastav R; Sapienza CM
    J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
    Boutsen F; Cannito MP; Taylor M; Bender B
    J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
    Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
    Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
    Lerner MZ; Lerner BA; Patel AA; Blitzer A
    Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of botulinum toxin type A in neuro-ORL].
    Périé S; Lacau St Guily J
    Ann Readapt Med Phys; 2003 Jul; 46(6):375-9. PubMed ID: 12928145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction.
    Schönweiler R; Wohlfarth K; Dengler R; Ptok M
    Laryngoscope; 1998 Jan; 108(1 Pt 1):55-63. PubMed ID: 9432068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia.
    Lundy DS; Lu FL; Casiano RR; Xue JW
    J Voice; 1998 Dec; 12(4):460-6. PubMed ID: 9988033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
    Holzer SE; Ludlow CL
    Laryngoscope; 1996 Jan; 106(1 Pt 1):86-92. PubMed ID: 8544635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia.
    Vasconcelos S; Birkent H; Sardesai MG; Merati AL; Hillel AD
    Laryngoscope; 2009 Oct; 119(10):2004-7. PubMed ID: 19572275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrasound-guided botulinum toxin injections and EMG biofeedback therapy the lower limb muscle spasm after cerebral infarction.
    Chen HX; Wang W; Xiao HQ; Wang H; Ding XD
    Eur Rev Med Pharmacol Sci; 2015; 19(9):1696-9. PubMed ID: 26004611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interarytenoid botulinum toxin A injection for the treatment of vocal process granuloma.
    Hamdan AL; Khalifee E; Jaffal H; Ghanem A
    J Laryngol Otol; 2019 Dec; 133(12):1041-1045. PubMed ID: 31711548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor.
    Estes C; Sadoughi B; Coleman R; Sarva H; Mauer E; Sulica L
    Laryngoscope; 2018 Feb; 128(2):437-446. PubMed ID: 28988441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of repeated botulinum toxin injections as a function of timing.
    Inagi K; Ford CN; Rodriquez AA; Schultz E; Bless DM; Heisey DM
    Ann Otol Rhinol Laryngol; 1997 Dec; 106(12):1012-9. PubMed ID: 9415596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.